NCT06006702View on ClinicalTrials.gov

A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions

Healthy

Interventions

DRUG

TYRA-300-B01

TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors

lead

Tyra Biosciences, Inc

INDUSTRY

NCT06006702 - A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants | Biotech Hunter | Biotech Hunter